Yasuhiro Yamada, executive director of Rohto Pharmaceutical, named chairman of the Buffalo, New-York based OTC maker. Rohto purchased the business from the Hyde family, which had run Mentholatum since its founding in 1889, in June. Former chairman George Hyde is now president. Shoji Yoshida, managing director of Rohto, is VP. Rohto had been Mentholatum's exclusive licensee in Japan since 1975.
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.